Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
暂无分享，去创建一个
S. Oka | C. Orkin | Kimberly Smith | H. Crauwels | V. van Eygen | W. Spreen | D. Margolis | O. Degen | A. Cutrell | P. Philibert | M. S. St. Clair | C. Brinson | S. Ford | P. Patel | R. van Solingen-Ristea | K. Vandermeulen | S. Vanveggel | D. Gusev | E. Morell | D. Dorey | Sandy Griffith | V. Chounta | R. D'Amico | J. García | S. Thiagarajah | D. Tan | A. Bassa | R. V. Van Solingen-Ristea | Kati Vandermeulen